As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits down with Philip B. Adamson, MD, MSc, FACC, Chief Medical Officer of CVRx, to talk about health equity — starting at the beginning of clinical trials, and including how medical device manufacturers need a clear roadmap from the get-go to achieve success.
As Chief Medical Officer of CVRx, Dr. Adamson will spearhead efforts to drive awareness and appropriate use of Barostim therapy among clinicians. He will guide comprehensive medical education, outreach and guideline integration initiatives to establish Barostim as the standard of care for patients with heart failure. Dr. Adamson previously was with Abbott Laboratories, where he served as Divisional Vice President and Chief Medical Officer of the Heart Failure division. A renowned expert in heart failure, he has nearly three decades of experience in academia as a professor and as a practicing cardiologist, during which time he authored over 150 manuscripts and book chapters. Dr. Adamson earned his MD with distinction from the University of Oklahoma College of Medicine and MSc in physiology from the University of Oklahoma.
His clinical interests focus on developing more efficient and effective disease management systems for patients with chronic heart failure, specifically focusing on remote monitoring of physiologic signals from implanted devices. He has also served as the principal investigator on the steering committees of several large randomized clinical trials over the past decade.
Related content:
DAIC Thought Leadership Series: Practical Realities of Artificial Intelligence in Echocardiology
DAIC Thought Leadership Series: Collaboration Challenges in Complex Cardiology Settings
